StockData
NeuroPace Inc logo

NeuroPace Inc (NPCE) stock

NPCENasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/3029% above fair value
$8.22+0.02 (+0.24%)

Close on Nov 18, 2026Market cap $282.15MP/E –Yield 0.00%

NeuroPace gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

NeuroPace's gross profit for the twelve months ending Jun 30, 2026 was $78.70M, up 20.8% year over year. For fiscal 2025 it was $77.22M, up 30.7% from the year before. The highest annual figure on record is $77.22M in fiscal 2025.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$77.22M+30.7%
FY2024Dec 31, 2024$59.09M+22.8%
FY2023Dec 31, 2023$48.12M+48.1%
FY2022Dec 31, 2022$32.49M-2.8%
FY2021Dec 31, 2021$33.44M+10.4%
FY2020Dec 31, 2020$30.27M–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$18.91M+16.6%
Q1 FY2026Mar 31, 2026$18.05M+4.1%
Q4 FY2025Dec 31, 2025$20.58M+27.1%
Q3 FY2025Sep 30, 2025$21.17M+37.3%
Q2 FY2025Jun 30, 2025$16.21M+14.7%
Q1 FY2025Mar 31, 2025$17.34M+30.0%
Q4 FY2024Dec 31, 2024$16.19M+19.5%
Q3 FY2024Sep 30, 2024$15.42M+26.1%
Q2 FY2024Jun 30, 2024$14.13M+18.1%
Q1 FY2024Mar 31, 2024$13.34M+28.6%
Q4 FY2023Dec 31, 2023$13.55M+53.9%
Q3 FY2023Sep 30, 2023$12.23M+53.6%
Q2 FY2023Jun 30, 2023$11.97M+60.4%
Q1 FY2023Mar 31, 2023$10.37M+25.6%
Q4 FY2022Dec 31, 2022$8.80M+9.0%
Q3 FY2022Sep 30, 2022$7.97M+6.1%
Q2 FY2022Jun 30, 2022$7.47M-20.2%
Q1 FY2022Mar 31, 2022$8.26M-2.8%
Q4 FY2021Dec 31, 2021$8.08M-1.7%
Q3 FY2021Sep 30, 2021$7.51M-21.6%
Q2 FY2021Jun 30, 2021$9.36M+72.6%
Q1 FY2021Mar 31, 2021$8.49M+20.3%
Q4 FY2020Dec 31, 2020$8.22M–
Q3 FY2020Sep 30, 2020$9.58M–
Q2 FY2020Jun 30, 2020$5.42M–
Q1 FY2020Mar 31, 2020$7.06M–

More NeuroPace figures

See a number that looks wrong?